)
Edge20 Feb 2026
Dollar General: The Rural Retailer Playbook
How Dollar General built a small-box empire across rural America, scaling value and convenience into one of retail's most durable business models.
BB Biotech
BB Biotech (BION) investor relations material
BB Biotech Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary20 Feb, 2026
Executive summary
Achieved net profit of CHF 578 million for 2025, up from CHF 76 million in 2024, with Q4 net profit at CHF 472 million, reflecting strong year-end momentum.
Delivered total returns of +34.2% in CHF, +37.0% in EUR, and +53.7% in USD, outperforming the Nasdaq Biotechnology Index in USD.
Five portfolio companies were acquired in 2025, validating the focus on clinically mature, differentiated assets.
Proposed dividend of CHF 2.25 per share and launched a new share buyback program of up to 10% over three years.
Portfolio strategy emphasized disciplined capital allocation, structural M&A exposure, and a catalyst-rich selection.
Financial highlights
Net asset value increased by 26.5% in CHF, 27.8% in EUR, and 44.8% in USD for 2025.
Share price outperformed, rising 34.2% in CHF, 37.0% in EUR, and 53.7% in USD year-over-year.
Outperformed the Nasdaq Biotech Index, which rose 16.6% in CHF and 33.4% in USD.
Discount to NAV narrowed from 15.2% to 10.8% at year-end 2025, further tightening to 8% in early 2026.
Portfolio ended 2025 with CHF 2,681.9 million in securities and a NAV of CHF 2,778.8 million.
Outlook and guidance
Entering 2026 with a diversified set of high-impact milestones across core positions, reducing dependence on single binary events.
Portfolio positioned for late-stage clinical, regulatory, and commercial milestones in 2026, with focus on immunology, oncology, and rare diseases.
Expecting a catalyst-rich year with multiple phase III data readouts and commercial launches in key portfolio companies.
Continued focus on clinically mature, strategically relevant assets aligned with big pharma needs.
Proposed dividend of CHF 2.25 per share and new share buyback program up to 10% over three years.
Value realization from Q4 portfolio acquisitions
Portfolio positioning given biotech valuation dispersion
Share buyback program's role in shareholder returns
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next BB Biotech earnings date
Q1 202624 Apr, 2026
BB Biotech
Next BB Biotech earnings date
Q1 202624 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
BB Biotech AG is an investment company specializing in biotechnology. The company focuses on building a diversified portfolio of publicly listed biotech companies, primarily in the fields of drug development and medical research. BB Biotech's investments target companies involved in innovative treatments for diseases across therapeutic areas such as oncology, rare diseases, and infectious diseases. The company is headquartered in Schaffhausen, Switzerland, and its shares are listed on the SIX.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage